Drug Trial Radar · NCT07295847
A Study of AZD0120 in Autoimmune Diseases
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Jan 9, 2026
Primary completion
Feb 22, 2028
Study completion Feb 22, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
Conditions
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathies
- Rheumatoid Arthritis
Interventions
AZD0120Biological
CD19/BCMA Autologous CAR T-cell therapy product
SOCDrug
SOC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)Time frame: 1 year
- Proportion of Participants Achieving a Revised-CRISS ResponseTime frame: Baseline, Week 52
- Proportion of participants achieving TIS response and low corticosteroid doseTime frame: Baseline, Week 52
- Proportion of participants achieving Disease Activity Score 28 C reactive protein (DAS28-CRP) < 2.6Time frame: Baseline, Week 12
Locations
27 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona · Not yet recruiting
Research Site
Duarte, California · Not yet recruiting
Research Site
Stanford, California · Not yet recruiting
Research Site
Miami, Florida · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Recruiting
Research Site
Chapel Hill, North Carolina · Recruiting
Research Site
Seattle, Washington · Not yet recruiting
Research Site
Clayton, Australia · Not yet recruiting
Research Site
Darlinghurst, Australia · Recruiting
Research Site
Waratah, Australia · Not yet recruiting
Research Site
Berlin, Germany · Not yet recruiting
Research Site
Erlangen, Germany · Not yet recruiting
Research Site
Hamburg, Germany · Not yet recruiting
Research Site
Jena, Germany · Not yet recruiting
Research Site
Mainz, Germany · Not yet recruiting
Research Site
Würzburg, Germany · Not yet recruiting
Research Site
Barcelona, Spain · Not yet recruiting
Research Site
Madrid, Spain · Not yet recruiting
Research Site
Madrid, Spain · Not yet recruiting
Research Site
Huddinge, Sweden · Not yet recruiting
Research Site
Edinburgh, United Kingdom · Recruiting
Research Site
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.